ABOS
Price:
$2.37
Market Cap:
$142.39M
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.[Read more]
Industry
Biotechnology
IPO Date
2021-07-01
Stock Exchange
NASDAQ
Ticker
ABOS
According to Acumen Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.14. This represents a change of -36.52% compared to the average of -3.37 of the last 4 quarters.
The mean historical PE Ratio of Acumen Pharmaceuticals, Inc. over the last ten years is -44.66. The current -2.14 PE Ratio has changed 379.13% with respect to the historical average. Over the past ten years (40 quarters), ABOS's PE Ratio was at its highest in in the June 2024 quarter at -1.74. The PE Ratio was at its lowest in in the December 2020 quarter at -190.70.
Average
-44.66
Median
-5.42
Minimum
-110.19
Maximum
-1.51
Discovering the peaks and valleys of Acumen Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 259.70%
Maximum Annual PE Ratio = -1.51
Minimum Annual Increase = -98.63%
Minimum Annual PE Ratio = -110.19
Year | PE Ratio | Change |
---|---|---|
2023 | -3.56 | -34.36% |
2022 | -5.42 | 259.70% |
2021 | -1.51 | -98.63% |
2020 | -110.19 | 7.35% |
The current PE Ratio of Acumen Pharmaceuticals, Inc. (ABOS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.49
5-year avg
-44.66
10-year avg
-44.66
Acumen Pharmaceuticals, Inc.’s PE Ratio is greater than Terns Pharmaceuticals, Inc. (-6.42), less than X4 Pharmaceuticals, Inc. (7.06), greater than Day One Biopharmaceuticals, Inc. (-7.33), less than HOOKIPA Pharma Inc. (-1.04), less than Amylyx Pharmaceuticals, Inc. (-1.28), greater than Inozyme Pharma, Inc. (-3.62), greater than Mereo BioPharma Group plc (-18.52),
Company | PE Ratio | Market cap |
---|---|---|
-6.42 | $698.29M | |
7.06 | $104.67M | |
-7.33 | $1.24B | |
-1.04 | $136.28M | |
-1.28 | $212.42M | |
-3.62 | $324.34M | |
-18.52 | $676.56M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Acumen Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Acumen Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Acumen Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Acumen Pharmaceuticals, Inc. (ABOS)?
What is the highest PE Ratio for Acumen Pharmaceuticals, Inc. (ABOS)?
What is the 3-year average PE Ratio for Acumen Pharmaceuticals, Inc. (ABOS)?
What is the 5-year average PE Ratio for Acumen Pharmaceuticals, Inc. (ABOS)?
How does the current PE Ratio for Acumen Pharmaceuticals, Inc. (ABOS) compare to its historical average?